Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses

References

• Cattaneo R, Miest T, Shashkova EV, et al. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol. 2008 Jul;6(7):529–540.
   PubMed Web of Science ®Google Scholar
• Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007 Apr;15(4):651–659.
   PubMed Web of Science ®Google Scholar
• Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022 Apr 6;7(1):117.
   PubMed Web of Science ®Google Scholar
• Davola ME, Mossman KL. Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? Oncoimmunology. 2019;8(6):e1581528.
   PubMed Web of Science ®Google Scholar
• Greber UF, Flatt JW. Adenovirus entry: from infection to immunity. Annu Rev Virol. 2019 Sep 29; 6(1):177–197.
   PubMedGoogle Scholar
• Reddy VS, Yu X, Barry MA. Refined capsid structure of human adenovirus D26 at 3.4 A resolution. Viruses. 2022 Feb 17; 14(2):414.
   PubMed Web of Science ®Google Scholar
• Lusky M. Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther. 2005 Mar;16(3):281–291.
   PubMed Web of Science ®Google Scholar
• Croyle MA, Cheng X, Sandhu A, et al. Development of novel formulations that enhance adenoviral-mediated gene expression in the lung in vitro and in vivo. Mol Ther. 2001 Jul;4(1):22–28.
   PubMed Web of Science ®Google Scholar
• Evans RK, Nawrocki DK, Isopi LA, et al. Development of stable liquid formulations for adenovirus-based vaccines. J Pharm Sci. 2004 Oct;93(10):2458–2475.
   PubMed Web of Science ®Google Scholar
• Bajrovic I, Schafer SC, Romanovicz DK, et al. Novel technology for storage and distribution of live vaccines and other biological medicines at ambient temperature. Sci Adv. 2020 Mar;6(10):eaau4819.
   PubMed Web of Science ®Google Scholar
• Kumru OS, Joshi SB, Smith DE, et al. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals. 2014 Sep;42(5):237–259.
   PubMed Web of Science ®Google Scholar
• Barefoot B, Thornburg NJ, Barouch DH, et al. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine. 2008 Nov 11;26(48):6108–6118.
   PubMed Web of Science ®Google Scholar
• Davison AJ, Benko M, Harrach B. Genetic content and evolution of adenoviruses. J Gen Virol. 2003 Nov;84(Pt 11):2895–2908.
   PubMed Web of Science ®Google Scholar
• Nicklin SA, Wu E, Nemerow GR, et al. The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther. 2005 Sep;12(3):384–393.
   PubMed Web of Science ®Google Scholar
• Arnberg N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol. 2009 May;19(3):165–178.
   PubMed Web of Science ®Google Scholar
• Barry MA, Weaver EA, Chen CY. Mining the adenovirus “virome” for systemic oncolytics. Curr Pharm Biotechnol. 2012 Jul;13(9):1804–1808.
   PubMed Web of Science ®Google Scholar
• Parker AL, Waddington SN, Nicol CG, et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood. 2006 Oct 15;108(8):2554–2561.
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Gaggar A, Ni S, et al. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol. 2005 Jun;79(12):7478–7491.
   PubMed Web of Science ®Google Scholar
• Xu Z, Tian J, Smith JS, et al. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol. 2008 Dec;82(23):11705–11713.
   PubMed Web of Science ®Google Scholar
• Xu Z, Qiu Q, Tian J, et al. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med. 2013 Apr;19(4):452–457.
   PubMed Web of Science ®Google Scholar
• Santra S, Sun Y, Korioth-Schmitz B, et al. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine. 2009 Sep 25;27(42):5837–5845.
   PubMed Web of Science ®Google Scholar
• Lemckert AA, Sumida SM, Holterman L, et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol. 2005 Aug;79(15):9694–9701.
   PubMed Web of Science ®Google Scholar
• Roberts DM, Nanda A, Havenga MJ, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006 May 11;441(7090):239–243.
   PubMed Web of Science ®Google Scholar
• Greber UF, Willetts M, Webster P, et al. Stepwise dismantling of adenovirus 2 during entry into cells. Cell. 1993 Nov 5;75(3):477–486.
   PubMed Web of Science ®Google Scholar
• Wickham TJ, Mathias P, Cheresh DA, et al. Integrins avb3 or avb5 promote adenovirus internalization but not virus attachment. Cell. 1993;73(2):309–319.
   PubMed Web of Science ®Google Scholar
• Huang S, Kamata T, Takada Y, et al. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol. 1996;70(7):4502–4508.
   PubMed Web of Science ®Google Scholar
• Farley DC, Brown JL, Leppard KN. Activation of the early-late switch in adenovirus type 5 major late transcription unit expression by L4 gene products. J Virol. 2004 Feb;78(4):1782–1791.
   PubMed Web of Science ®Google Scholar
• Fessler SP, Young CS. Control of adenovirus early gene expression during the late phase of infection. J Virol. 1998 May;72(5):4049–4056.
   PubMed Web of Science ®Google Scholar
• Crisostomo L, Soriano AM, Mendez M, et al. Temporal dynamics of adenovirus 5 gene expression in normal human cells. PLoS One. 2019;14(1):e0211192.
   PubMed Web of Science ®Google Scholar
• Tormanen H, Backstrom E, Carlsson A, et al. L4-33K, an adenovirus-encoded alternative RNA splicing factor. J Biol Chem. 2006 Dec 1;281(48):36510–36517
   PubMed Web of Science ®Google Scholar
• Morris SJ, Scott GE, Leppard KN. Adenovirus late-phase infection is controlled by a novel L4 promoter. J Virol. 2010 Jul;84(14):7096–7104.
   PubMed Web of Science ®Google Scholar
• Turner MA, Middha S, Hofherr SE, et al. Comparison of the life cycles of genetically distant species C and species D human adenoviruses Ad6 and Ad26 in human cells. J Virol. 2015 Dec;89(24):12401–12417.
   PubMed Web of Science ®Google Scholar
• Jakobsson AW, Segerman B, Wallerman O, et al. The human Adenovirus 2 transcriptome: an amazing complexity of alternatively spliced mRNAs. J Virol. 2021;95(4):e01869–20. ** An important study demonstrating the complexity of mRNA splicing of adenoviruses by long-read next-generation sequencing.
   PubMed Web of Science ®Google Scholar
• Senac JS, Doronin K, Russell SJ, et al. Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther. 2010 Feb;21(2):179–190.
   PubMed Web of Science ®Google Scholar
• Zhao H, Granberg F, Pettersson U. How adenovirus strives to control cellular gene expression. Virology. 2007 Jul 5; 363(2):357–375.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhou P, Ge X, et al. Deep RNA sequencing reveals complex transcriptional landscape of a bat adenovirus. J Virol. 2013 Jan;87(1):503–511.
   PubMed Web of Science ®Google Scholar
• Donovan-Banfield I, Turnell AS, Hiscox JA, et al. Deep splicing plasticity of the human adenovirus type 5 transcriptome drives virus evolution. Commun Biol. 2020 Mar 13;3(1):124.
   PubMed Web of Science ®Google Scholar
• Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol. 1993 Oct;67(10):5911–5921.
   PubMed Web of Science ®Google Scholar
• Lichtenstein DL, Toth K, Doronin K, et al. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol. 2004 Jan-Apr;23(1–2):75–111.
   PubMed Web of Science ®Google Scholar
• Horwitz MS. Function of adenovirus E3 proteins and their interactions with immunoregulatory cell proteins. J Gene Med. 2004 Feb;6(1):S172–83.
   PubMedGoogle Scholar
• Robinson CM, Singh G, Lee JY, et al. Molecular evolution of human adenoviruses. Sci Rep. 2013;3(1):1812.
   PubMedGoogle Scholar
• Hawkins LK, Wold WSM. Wold WS. A 12,500 MW protein is coded by region E3 of adenovirus. Virology. 1992 Jun;188(2):486–494.
   PubMed Web of Science ®Google Scholar
• Moise AR, Grant JR, Vitalis TZ, et al. Adenovirus E3-6.7K maintains calcium homeostasis and prevents apoptosis and arachidonic acid release. J Virol. 2002 Feb;76(4):1578–1587.
   PubMed Web of Science ®Google Scholar
• Lichtenstein DL, Doronin K, Toth K, et al. Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2. J Virol. 2004 Nov;78(22):12297–12307.
   PubMed Web of Science ®Google Scholar
• Burgert HG, Maryanski JL, Kvist S. “E3/19K” protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens. Proc. Natl. Acad. Sci. USA. 1987;84(5):1356–1360.
   PubMed Web of Science ®Google Scholar
• Georgi F, Greber UF. The adenovirus death protein - a small membrane protein controls cell lysis and disease. FEBS Lett. 2020 Jun;594(12):1861–1878.
   PubMed Web of Science ®Google Scholar
• Robertson MG, Eidenschink BB, Iguchi E, et al. Cancer imaging and therapy utilizing a novel NIS-expressing adenovirus: the role of adenovirus death protein deletion. Mol Ther Oncolytics. 2021 Mar 26;20:659–668. 10.1016/j.omto.2021.03.002.
   PubMed Web of Science ®Google Scholar
• Shisler J, Yang C, Walter B, et al. The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J Virol. 1997 Nov;71(11):8299–8306.
   PubMed Web of Science ®Google Scholar
• Tollefson AE, Hermiston TW, Lichtenstein DL, et al. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature. 1998 Apr 16;392(6677):726–730.
   PubMed Web of Science ®Google Scholar
• Lichtenstein DL, Krajcsi P, Esteban DJ, et al. Adenovirus RIDbeta subunit contains a tyrosine residue that is critical for RID-mediated receptor internalization and inhibition of Fas- and TRAIL-induced apoptosis. J Virol. 2002 Nov;76(22):11329–11342.
   PubMed Web of Science ®Google Scholar
• Horton TM, Ranheim TS, Aquino L, et al. Adenovirus E3 14.7K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis. J Virol. 1991 May;65(5):2629–2639.
   PubMed Web of Science ®Google Scholar
• Schneider-Brachert W, Tchikov V, Merkel O, et al. Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism. J Clin Invest. 2006 Nov;116(11):2901–2913.
   PubMed Web of Science ®Google Scholar
• Tollefson AE, Ying B, Doronin K, et al. Identification of a new human adenovirus protein encoded by a novel late l-strand transcription unit. J Virol. 2007 Dec;81(23):12918–12926.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hallden G, Hill R, et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol. 2003 Nov;21(11):1328–1335.
   PubMed Web of Science ®Google Scholar
• Bortolanza S, Bunuales M, Alzuguren P, et al. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters. Cancer Gene Ther. 2009 Sep;16(9):703–712.
   PubMed Web of Science ®Google Scholar
• Bos JL, Polder LJ, Bernards R, et al. The 2.2 kb E1b mRNA of human Ad12 and Ad5 codes for two tumor antigens starting at different AUG triplets. Cell. 1981 Nov;27(1 Pt 2):121–131.
   PubMed Web of Science ®Google Scholar
• Han J, Sabbatini P, Perez D, et al. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev. 1996 Feb 15;10(4):461–477.
   PubMed Web of Science ®Google Scholar
• Hidalgo P, Ip WH, Dobner T, et al. The biology of the adenovirus E1B 55K protein. FEBS Lett. 2019 Dec;593(24):3504–3517.
   PubMed Web of Science ®Google Scholar
• Doloff JC, Waxman DJ, Jounaidi Y. Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa Gene deletions. Hum Gene Ther. 2008 Dec;19(12):1383–1399.
   PubMed Web of Science ®Google Scholar
• Cheng PH, Wechman SL, McMasters KM, et al. Oncolytic replication of E1b-deleted adenoviruses. Viruses. 2015 Nov 6;7(11):5767–5779.
   PubMed Web of Science ®Google Scholar
• Sauthoff H, Heitner S, Rom WN, et al. Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther. 2000 Feb 10;11(3):379–388.
   PubMed Web of Science ®Google Scholar
• Harrison D, Sauthoff H, Heitner S, et al. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved–deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum Gene Ther. 2001 Jul 1;12(10):1323–1332.
   PubMed Web of Science ®Google Scholar
• Crosby CM, Barry MA. IIIa deleted adenovirus as a single-cycle genome replicating vector. Virology. 2014 Aug;462-463:158–165.
   PubMed Web of Science ®Google Scholar
• Crosby CM, Barry MA. Transgene expression and host cell responses to replication-defective, single-cycle, and replication-competent adenovirus vectors. Genes (Basel). 2017 Feb 18; 8(2):79.
   PubMed Web of Science ®Google Scholar
• Farrera-Sal M, Fillat C, Alemany R. Effect of transgene location, transcriptional control elements and transgene features in armed oncolytic adenoviruses. Cancers (Basel). 2020 Apr 23; 12(4):1034.
   PubMed Web of Science ®Google Scholar
• Kretschmer PJ, Jin F, Chartier C, et al. Development of a transposon-based approach for identifying novel transgene insertion sites within the replicating adenovirus. Mol Ther. 2005 Jul;12(1):118–127.
   PubMed Web of Science ®Google Scholar
• Jin F, Kretschmer PJ, Hermiston TW. Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression. Mol Ther. 2005 Dec;12(6):1052–1063.
   PubMed Web of Science ®Google Scholar
• Wang M, Marin A. Characterization and prediction of alternative splice sites. Gene. 2006 Feb 1; 366(2):219–227.
   PubMed Web of Science ®Google Scholar
• Cartegni L, Wang J, Zhu Z, et al. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003 Jul 1;31(13):3568–3571.
   PubMed Web of Science ®Google Scholar
• Hawkins LK, Hermiston T. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Ther. 2001 Aug;8(15):1142–1148.
   PubMed Web of Science ®Google Scholar
• Hawkins LK, Hermiston TW. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region. Gene Ther. 2001 Aug;8(15):1132–1141.
   PubMed Web of Science ®Google Scholar
• Hawkins LK, Johnson L, Bauzon M, et al. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region. Gene Ther. 2001 Aug;8(15):1123–1131.
   PubMed Web of Science ®Google Scholar
• Bauzon M, Castro D, Karr M, et al. Multigene expression from a replicating adenovirus using native viral promoters. Mol Ther. 2003 Apr;7(4):526–534.
   PubMed Web of Science ®Google Scholar
• Shashkova EV, Spencer JF, Wold WS, et al. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther. 2007 Mar;15(3):598–607.
   Web of Science ®Google Scholar
• Shaul O. How introns enhance gene expression. Int J Biochem Cell Biol. 2017 Oct;91(Pt B):145–155.
   PubMedGoogle Scholar
• Martinez-Salas E, Francisco-Velilla R, Fernandez-Chamorro J, et al. Insights into structural and mechanistic features of viral IRES elements. Front Microbiol. 2017;8:2629.
   PubMed Web of Science ®Google Scholar
• Rivera AA, Wang M, Suzuki K, et al. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. Virology. 2004 Mar 1;320(1):121–134.
   PubMed Web of Science ®Google Scholar
• Sharma P, Yan F, Doronina VA, et al. 2A peptides provide distinct solutions to driving stop-carry on translational recoding. Nucleic Acids Res. 2012 Apr;40(7):3143–3151.
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen O, Wall JBJ, et al. Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Sci Rep. 2017 May 19;7(1):2193.
   PubMedGoogle Scholar
• Funston GM, Kallioinen SE, de Felipe P, et al. Expression of heterologous genes in oncolytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping. J Gen Virol. 2008 Feb;89(Pt 2):389–396.
   PubMedGoogle Scholar
• Quirin C, Rohmer S, Fernandez-Ulibarri I, et al. Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy. Hum Gene Ther. 2011 Apr;22(4):389–404.
   PubMed Web of Science ®Google Scholar
• Hagihara Y, Sakamoto A, Tokuda T, et al. Photoactivatable oncolytic adenovirus for optogenetic cancer therapy. Cell Death Dis. 2020 Jul 23;11(7):570.
   PubMed Web of Science ®Google Scholar
• Muhlemann O, Yue BG, Petersen-Mahrt S, et al. A novel type of splicing enhancer regulating adenovirus pre-mRNA splicing. Mol Cell Biol. 2000 Apr;20(7):2317–2325.
   PubMed Web of Science ®Google Scholar
• Carette JE, Graat HC, Schagen FH, et al. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. J Gene Med. 2005 Aug;7(8):1053–1062.
   PubMed Web of Science ®Google Scholar
• Fuerer C, Iggo R. 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene. Gene Ther. 2004 Jan;11(2):142–151.
   PubMed Web of Science ®Google Scholar
• Berg M, Difatta J, Hoiczyk E, et al. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit. Proc Natl Acad Sci USA. 2005 Mar 22;102(12):4590–4595.
   PubMed Web of Science ®Google Scholar
• Fernandez-Ulibarri I, Hammer K, Arndt MA, et al. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Int J Cancer. 2015 May 1;136(9):2228–2240.
   PubMed Web of Science ®Google Scholar
• Robinson M, Ge Y, Ko D, et al. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression [Comparative Study]. Cancer Gene Ther. 2008 Jan;15(1):9–17.
   PubMed Web of Science ®Google Scholar
• Farrera-Sal M, de Sostoa J, Nunez-Manchon E, et al. Arming oncolytic adenoviruses: effect of insertion site and splice acceptor on transgene expression and viral fitness. Int J Mol Sci. 2020 Jul 21;21(14):5158.
   PubMed Web of Science ®Google Scholar
• Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022 Apr;22(4):209–223.
   PubMed Web of Science ®Google Scholar
• Wan PK, Ryan AJ, Seymour LW. Beyond cancer cells: targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Mol Ther. 2021 May 5; 29(5):1668–1682.
   PubMed Web of Science ®Google Scholar
• Boagni DA, Ravirala D, Zhang SX. Current strategies in engaging oncolytic viruses with antitumor immunity. Mol Ther Oncolytics. 2021 Sep 24; 22:98–113.
   PubMed Web of Science ®Google Scholar
• Rahman MM, McFadden G. Oncolytic viruses: newest frontier for cancer immunotherapy. Cancers (Basel). 2021 Oct 29; 13(21):5452.
   PubMed Web of Science ®Google Scholar
• Xing Y, Hogquist KA. T-cell tolerance: central and peripheral. Cold Spring Harb Perspect Biol. 2012 Jun 1; 4(6):a006957.
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019 Jul 16; 51(1):27–41.
   PubMed Web of Science ®Google Scholar
• Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021;12:636568.
   PubMed Web of Science ®Google Scholar
• Wolf Y, Samuels Y. Intratumor heterogeneity and antitumor immunity shape one another bidirectionally. Clin Cancer Res. 2022 Jul 15; 28(14):2994–3001.
   PubMed Web of Science ®Google Scholar
• Archilla-Ortega A, Domuro C, Martin-Liberal J, et al. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity. J Exp Clin Cancer Res. 2022 Feb 14;41(1):62.
   PubMed Web of Science ®Google Scholar
• Lubbers J, Rodriguez E, van Kooyk Y. Modulation of immune tolerance via siglec-sialic acid interactions. Front Immunol. 2018;9:2807.
   PubMed Web of Science ®Google Scholar
• Follain G, Herrmann D, Harlepp S, et al. Fluids and their mechanics in tumour transit: shaping metastasis. Nat Rev Cancer. 2020 Feb;20(2):107–124.
   PubMed Web of Science ®Google Scholar
• Simsek H, Klotzsch E. The solid tumor microenvironment-breaking the barrier for T cells: how the solid tumor microenvironment influences T cells: how the solid tumor microenvironment influences T cells. Bioessays. 2022 Jun;44(6):e2100285.
   PubMed Web of Science ®Google Scholar
• Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015 Nov;15(11):669–682.
   PubMed Web of Science ®Google Scholar
• Sackstein R, Schatton T, Barthel SR. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab Invest. 2017 Jun;97(6):669–697.
   PubMed Web of Science ®Google Scholar
• Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020 Aug 17; 30(16):R921–R925.
   PubMed Web of Science ®Google Scholar
• DePeaux K, Delgoffe GM. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021 Dec;21(12):785–797.
   PubMed Web of Science ®Google Scholar
• Watson MJ, Delgoffe GM. Fighting in a wasteland: deleterious metabolites and antitumor immunity. J Clin Invest. 2022 Jan 18; 132(2):e148549.
   PubMed Web of Science ®Google Scholar
• Aldhamen YA, Appledorn DM, Seregin SS, et al. Expression of the SLAM family of receptors adapter EAT-2 as a novel strategy for enhancing beneficial immune responses to vaccine antigens. J Immunol. 2011 Jan 15;186(2):722–732.
   PubMed Web of Science ®Google Scholar
• O’Connell P, Blake MK, Pepelyayeva Y, et al. Adenoviral delivery of an immunomodulatory protein to the tumor microenvironment controls tumor growth. Mol Ther Oncolytics. 2022 Mar 17;24:180–193.
   PubMed Web of Science ®Google Scholar
• Ramachandran M, Yu D, Wanders A, et al. An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors. Mol Ther. 2013 Nov;21(11):2008–2018.
   PubMed Web of Science ®Google Scholar
• Liikanen I, Basnet S, Quixabeira DCA, et al. Oncolytic adenovirus decreases the proportion of TIM-3(+) subset of tumor-infiltrating CD8(+) T cells with correlation to improved survival in patients with cancer. J Immunother Cancer. 2022 Feb;10(2):e003490.
   PubMed Web of Science ®Google Scholar
• Raman SS, Hecht JR, Chan E. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy. 2019 Jun;11(8):705–723.
   PubMed Web of Science ®Google Scholar
• Kumar A, Taghi Khani A, Sanchez Ortiz A, et al. GM-CSF: a double-edged sword in cancer immunotherapy. Front Immunol. 2022;13:901277.
   PubMed Web of Science ®Google Scholar
• Mandai M, Hamanishi J, Abiko K, et al. Dual Faces of IFNgamma in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res. 2016 May 15;22(10):2329–2334.
   PubMed Web of Science ®Google Scholar
• Ge Y, Wang H, Ren J, et al. Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety. J Immunother Cancer. 2020 Mar;8(1):e000710.
   PubMed Web of Science ®Google Scholar
• Blair TC, Bambina S, Alice AF, et al. Dendritic cell maturation defines immunological responsiveness of tumors to radiation therapy. J Immunol. 2020 Jun 15;204(12):3416–3424.
   PubMed Web of Science ®Google Scholar
• Patente TA, Pinho MP, Oliveira AA, et al. Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy. Front Immunol. 2018;9:3176.
   PubMed Web of Science ®Google Scholar
• Diaconu I, Cerullo V, Hirvinen ML, et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res. 2012 May 1;72(9):2327–2338.
   PubMed Web of Science ®Google Scholar
• Pesonen S, Diaconu I, Kangasniemi L, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 2012 Apr 1;72(7):1621–1631.
   PubMed Web of Science ®Google Scholar
• Yang YF, Xue SY, Lu ZZ, et al. Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer. Gene Ther. 2014 Aug;21(8):723–731.
   PubMed Web of Science ®Google Scholar
• Eriksson E, Moreno R, Milenova I, et al. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment. Gene Ther. 2017 Feb;24(2):92–103.
   PubMed Web of Science ®Google Scholar
• Hirvinen M, Rajecki M, Kapanen M, et al. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus. Hum Gene Ther. 2015 Mar;26(3):134–144.
   PubMed Web of Science ®Google Scholar
• LaRocca CJ, Han J, Gavrikova T, et al. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Surgery. 2015 May;157(5):888–898.
   PubMed Web of Science ®Google Scholar
• LaRocca CJ, Salzwedel AO, Sato-Dahlman M, et al. Interferon alpha-expressing oncolytic adenovirus for treatment of esophageal adenocarcinoma. Ann Surg Oncol. 2021 Dec;28(13):8556–8564.
   PubMed Web of Science ®Google Scholar
• Burke JM, Lamm DL, Meng MV, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012 Dec;188(6):2391–2397.
   PubMed Web of Science ®Google Scholar
• Kanerva A, Nokisalmi P, Diaconu I, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013 May 15;19(10):2734–2744.
   PubMed Web of Science ®Google Scholar
• Du T, Shi G, Li YM, et al. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther. 2014 Aug;21(8):340–348.
   PubMed Web of Science ®Google Scholar
• Dobbins GC, Ugai H, Curiel DT, et al. A multi targeting conditionally replicating adenovirus displays enhanced oncolysis while maintaining expression of Immunotherapeutic agents. PLoS One. 2015;10(12):e0145272.
   PubMed Web of Science ®Google Scholar
• Vassilev L, Ranki T, Joensuu T, et al. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8(+) T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. Oncoimmunology. 2015 Jul;4(7):e1017702.
   PubMed Web of Science ®Google Scholar
• Wang L, Zheng J, He Q, et al. TOA02, a recombinant adenovirus with tumor-specific granulocyte macrophage colony-stimulating factor expression, has limited biodistribution and low toxicity in rhesus monkeys. Hum Gene Ther Methods. 2015 Apr;26(2):62–70.
   PubMed Web of Science ®Google Scholar
• Bramante S, Koski A, Liikanen I, et al. Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. Oncoimmunology. 2016 Feb;5(2):e1078057.
   PubMed Web of Science ®Google Scholar
• Moesta AK, Cooke K, Piasecki J, et al. Local Delivery of OncoVEX(mGM-CSF) generates systemic antitumor immune responses enhanced by cytotoxic T-lymphocyte-associated protein blockade. Clin Cancer Res. 2017 Oct 15;23(20):6190–6202.
   PubMed Web of Science ®Google Scholar
• Kuryk L, Moller AW, Garofalo M, et al. Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model. J Med Virol. 2018 Oct;90(10):1669–1673.
   PubMed Web of Science ®Google Scholar
• Su Y, Li J, Ji W, et al. Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors. J Immunother Cancer. 2022 May;10(5):e004691.
   PubMed Web of Science ®Google Scholar
• Ramachandran M, Jin C, Yu D, et al. Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration. J Immunol. 2014 Sep 1;193(5):2287–2296.
   PubMed Web of Science ®Google Scholar
• Kober J, Leitner J, Klauser C, et al. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol. 2008 Oct;38(10):2678–2688.
   PubMed Web of Science ®Google Scholar
• Martinez-Perez AG, Perez-Trujillo JJ, Garza-Morales R, et al. An oncolytic adenovirus encoding SA-4-1BBL adjuvant fused to HPV-16 E7 antigen produces a specific antitumor effect in a cancer mouse Model. Vaccines (Basel). 2021 Feb 12;9(2):149.
   PubMed Web of Science ®Google Scholar
• Laspidea V, Puigdelloses M, Labiano S, et al. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. JCI Insight. 2022 Apr 8;7(7):e154812.
   PubMed Web of Science ®Google Scholar
• Martinez-Velez N, Laspidea V, Zalacain M, et al. Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune memory. Mol Cancer Ther. 2022 Mar 1;21(3):471–480.
   PubMed Web of Science ®Google Scholar
• Jiang H, Rivera-Molina Y, Gomez-Manzano C, et al. Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res. 2017 Jul 15;77(14):3894–3907.
   PubMed Web of Science ®Google Scholar
• Andarini S, Kikuchi T, Nukiwa M, et al. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res. 2004 May 1;64(9):3281–3287.
   PubMed Web of Science ®Google Scholar
• Rivera-Molina Y, Jiang H, Fueyo J, et al. GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory. Neurooncol Adv. 2019 May-Dec;1(1):vdz009.
   PubMedGoogle Scholar
• Dai S, Lv Y, Xu W, et al. Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice. Cancer Gene Ther. 2020 Dec;27(12):923–933.
   PubMed Web of Science ®Google Scholar
• Garofalo M, Bertinato L, Staniszewska M, et al. Combination therapy of novel oncolytic adenovirus with anti-PD1 resulted in enhanced anti-cancer effect in syngeneic immunocompetent melanoma mouse model. Pharmaceutics. 2021 Apr 14;13(4):547.
   PubMed Web of Science ®Google Scholar
• Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003 Apr;3(4):269–279.
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol. [1998 Oct 1];161(7):3400–3407.
   PubMed Web of Science ®Google Scholar
• Santos JM, Havunen R, Siurala M, et al. Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy. Int J Cancer. 2017 Oct 1;141(7):1458–1468.
   PubMed Web of Science ®Google Scholar
• Quixabeira DCA, Zafar S, Santos JM, et al. Oncolytic adenovirus coding for a variant interleukin 2 (vIL-2) cytokine re-programs the tumor microenvironment and confers enhanced tumor control. Front Immunol. 2021;12:674400.
   PubMed Web of Science ®Google Scholar
• Huang J, Zheng M, Zhang Z, et al. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol Immunother. 2021 Sep;70(9):2453–2465.
   PubMed Web of Science ®Google Scholar
• Poutou J, Bunuales M, Gonzalez-Aparicio M, et al. Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model. Gene Ther. 2015 Sep;22(9):696–706.
   PubMed Web of Science ®Google Scholar
• Rosewell Shaw A, Porter CE, Watanabe N, et al. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer. Mol Ther. 2017 Nov 1;25(11):2440–2451.
   PubMed Web of Science ®Google Scholar
• Wang P, Li X, Wang J, et al. Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun. 2017 Nov 9;8(1):1395.
   PubMedGoogle Scholar
• Zhang Z, Zhang C, Miao J, et al. A tumor-targeted replicating oncolytic adenovirus ad-TD-nsIL12 as a promising therapeutic agent for human esophageal squamous cell carcinoma. Cells. 2020 Nov 10;9(11):2438.
   PubMed Web of Science ®Google Scholar
• Zalacain M, Bunuales M, Marrodan L, et al. Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma. Mol Ther Oncolytics. 2021 Mar 26;20:23–33.
   PubMed Web of Science ®Google Scholar
• Yan Y, Li S, Jia T, et al. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity. Tumour Biol. 2015 Jun;36(6):4535–4543.
   PubMedGoogle Scholar
• Zhang Q, Zhang J, Tian Y, et al. Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells. Cell Biosci. 2020;10(1):124.
   PubMed Web of Science ®Google Scholar
• Choi IK, Lee JS, Zhang SN, et al. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rbeta2 or IL-18Ralpha. Gene Ther. 2011 Sep;18(9):898–909.
   PubMed Web of Science ®Google Scholar
• Bunuales M, Ballesteros-Briones MC, Gonzalez-Aparicio M, et al. Adenovirus-mediated inducible expression of a PD-L1 blocking antibody in combination with macrophage depletion improves survival in a mouse model of peritoneal carcinomatosis. Int J Mol Sci. 2021 Apr 17;22(8):4176.
   PubMed Web of Science ®Google Scholar
• Hamdan F, Ylosmaki E, Chiaro J, et al. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. J Immunother Cancer. 2021 Aug;9(8):e003000.
   PubMed Web of Science ®Google Scholar
• Rosewell Shaw A, Porter CE, Yip T, et al. Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021 Mar 19;4(1):368.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang Y, Dong J, et al. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8(+) T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma. Cell Oncol (Dordr). 2021 Dec;44(6):1243–1255.
   PubMed Web of Science ®Google Scholar
• Vitale M, Scialo F, Passariello M, et al. Oncolytic adenoviral vector-mediated expression of an anti-PD-L1-scFv improves anti-tumoral efficacy in a melanoma mouse model. Front Oncol. 2022;12:902190.
   PubMed Web of Science ®Google Scholar
• Zhou P, Wang X, Xing M, et al. Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy. Mol Ther Oncolytics. 2022 Jun 16;25:236–248. 10.1016/j.omto.2022.04.007.
   PubMed Web of Science ®Google Scholar
• Tanoue K, Rosewell Shaw A, Watanabe N, et al. Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors. Cancer Res. 2017 Apr 15;77(8):2040–2051.
   PubMed Web of Science ®Google Scholar
• Huang Y, Lv SQ, Liu PY, et al. A SIRPalpha-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer. Mol Oncol. 2020 Mar;14(3):657–668.
   PubMed Web of Science ®Google Scholar
• Zhang B, Shu Y, Hu S, et al. In situ tumor vaccine expressing anti-CD47 antibody enhances antitumor immunity. Front Oncol. 2022;12:897561.
   PubMed Web of Science ®Google Scholar
• Takimoto CH, Chao MP, Gibbs C, et al. The macrophage ‘do not eat me’ signal, CD47, is a clinically validated cancer immunotherapy target. Ann Oncol. 2019 Mar 1;30(3):486–489.
   PubMed Web of Science ®Google Scholar
• Choi IK, Lee YS, Yoo JY, et al. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther. 2010 Feb;17(2):190–201.
   PubMed Web of Science ®Google Scholar
• Xu W, Neill T, Yang Y, et al. The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther. 2015 Mar;22(3):247–256.
   PubMed Web of Science ®Google Scholar
• Li Y, Hong J, Oh JE, et al. Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer. Int J Cancer. 2018 Jan 15;142(2):392–413.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee YS, Kim H, et al. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst. 2006 Oct 18;98(20):1482–1493.
   PubMedGoogle Scholar
• Jung BK, Ko HY, Kang H, et al. Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade. J Immunother Cancer. 2020 Aug;8(2):e000763.
   PubMed Web of Science ®Google Scholar
• Cheng J, Sauthoff H, Huang Y, et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther. 2007 Nov;15(11):1982–1990.
   PubMed Web of Science ®Google Scholar
• Garantziotis S, Savani RC. Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol. 2019 May;78-79:1–10.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Garcia A, Gimenez-Alejandre M, Rojas JJ, et al. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clin Cancer Res. 2015 Mar 15;21(6):1406–1418.
   PubMed Web of Science ®Google Scholar
• Bazan-Peregrino M, Garcia-Carbonero R, Laquente B, et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J Immunother Cancer. 2021 Nov;9(11):e003254.
   PubMed Web of Science ®Google Scholar
• Farrera-Sal M, Moreno R, Mato-Berciano A, et al. Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation. Mol Ther Oncolytics. 2021 Sep 24;22:27–35. 10.1016/j.omto.2021.05.009.
   PubMed Web of Science ®Google Scholar
• Kiyokawa J, Kawamura Y, Ghouse SM, et al. Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma. Clin Cancer Res. 2021 Feb 1;27(3):889–902.
   PubMed Web of Science ®Google Scholar
• Mato-Berciano A, Morgado S, Maliandi MV, et al. Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11. J Control Release. 2021 Apr 10;332:517–528. 10.1016/j.jconrel.2021.02.035.
   PubMed Web of Science ®Google Scholar
• Yumul R, Richter M, Lu ZZ, et al. Epithelial junction opener improves oncolytic adenovirus therapy in mouse tumor models. Hum Gene Ther. 2016 Apr;27(4):325–337.
   PubMed Web of Science ®Google Scholar
• Tedcastle A, Illingworth S, Brown A, et al. Actin-resistant DNAse I expression from oncolytic adenovirus enadenotucirev enhances its intratumoral Spread and reduces tumor growth. Mol Ther. 2016 Apr;24(4):796–804.
   PubMed Web of Science ®Google Scholar
• Li J, Liu H, Li L, et al. The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma. Oncol Rep. 2013 Mar;29(3):895–902.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Gores GJ, Corey KE. The two faces of relaxin in cancer: antitumor or protumor? Hepatology. 2020 Mar;71(3):1117–1119.
   PubMed Web of Science ®Google Scholar
• Ahn HM, Hong J, Yun CO. Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy. Oncotarget. 2016 Dec 20; 7(51):84965–84980.
   PubMedGoogle Scholar
• Kim BG, Malek E, Choi SH, et al. Novel therapies emerging in oncology to target the TGF-beta pathway. J Hematol Oncol. 2021 Apr 6;14(1):55.
   PubMed Web of Science ®Google Scholar
• Hu Z, Zhang Z, Guise T, et al. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-beta receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Hum Gene Ther. 2010 Nov;21(11):1623–1629.
   PubMed Web of Science ®Google Scholar
• Larson C, Oronsky B, Abrouk NE, et al. Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-beta. Am J Cancer Res. 2021;11(10):5184–5189.
   PubMed Web of Science ®Google Scholar
• Liu Z, Yang Y, Zhang X, et al. An Oncolytic adenovirus encoding decorin and granulocyte macrophage colony stimulating factor inhibits tumor growth in a colorectal tumor model by targeting pro-tumorigenic signals and via immune activation. Hum Gene Ther. 2017 Aug;28(8):667–680.
   PubMed Web of Science ®Google Scholar
• Kim SY, Kang D, Choi HJ, et al. Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-beta2 induces anti-tumor immune activation. Oncotarget. 2017 Feb 28;8(9):15858–15877.
   PubMedGoogle Scholar
• Freedman JD, Duffy MR, Lei-Rossmann J, et al. An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells. Cancer Res. 2018 Dec 15;78(24):6852–6865.
   PubMed Web of Science ®Google Scholar
• Scott EM, Jacobus EJ, Lyons B, et al. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples. J Immunother Cancer. 2019 Nov 21;7(1):320.
   PubMed Web of Science ®Google Scholar
• Shin SP, Goh AR, Ju JM, et al. Local adenoviral delivery of soluble CD200R-Ig enhances antitumor immunity by inhibiting CD200-beta-catenin-driven M2 macrophage. Mol Ther Oncolytics. 2021 Dec 17;23:138–150.
   PubMed Web of Science ®Google Scholar
• Kennedy BE, Sadek M, Gujar SA. Targeted metabolic reprogramming to improve the efficacy of oncolytic virus therapy. Mol Ther. 2020 Jun 3; 28(6):1417–1421.
   PubMed Web of Science ®Google Scholar
• Rivadeneira DB, DePeaux K, Wang Y, et al. Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. Immunity. 2019 Sep 17;51(3):548–560 e4.
   PubMed Web of Science ®Google Scholar
• Morsy MA, Gu M, Motzel S , et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA. 1998 Jul 7;95(14):7866–7871.
   PubMed Web of Science ®Google Scholar
• Eriksson E, Milenova I, Wenthe J, et al. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin Cancer Res. 2017 Oct 1;23(19):5846–5857.
   PubMed Web of Science ®Google Scholar
• Lu SC, Hansen MJ, Hemsath JR, et al. Modulating oncolytic adenovirus immunotherapy by driving two axes of the immune system by expressing 4-1BBL and CD40L. Hum Gene Ther. 2022 Mar;33(5–6):250–261.
   PubMed Web of Science ®Google Scholar
• Ylosmaki E, Ylosmaki L, Fusciello M, et al. Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform. Mol Ther Oncolytics. 2021 Mar 26;20:459–469.
   PubMed Web of Science ®Google Scholar
• Choi IK, Li Y, Oh E, et al. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-gamma- and TNF-alpha-co-producing T cell-mediated antitumor immunity. PLoS One. 2013;8(7):e67512.
   PubMed Web of Science ®Google Scholar
• Du YN, Wei Q, Zhao LJ, et al. Hydrogel-based co-delivery of CIK cells and oncolytic adenovirus armed with IL12 and IL15 for cancer immunotherapy. Biomed Pharmacother. 2022 Jul;151:113110.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang H, Wei M, et al. Recombinant adenovirus expressing a soluble fusion protein PD-1/CD137L subverts the suppression of CD8(+) T cells in HCC. Mol Ther. 2019 Nov 6;27(11):1906–1918.
   PubMed Web of Science ®Google Scholar
• Porter CE, Rosewell Shaw A, Jung Y, et al. Oncolytic adenovirus armed with bite, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors. Mol Ther. 2020 May 6;28(5):1251–1262.
   PubMed Web of Science ®Google Scholar
• Eriksson E, Milenova I, Wenthe J, et al. IL-6 Signaling blockade during CD40-mediated immune activation favors antitumor factors by reducing TGF-beta, collagen type I, and PD-L1/PD-1. J Immunol. 2019 Feb 1;202(3):787–798.
   PubMed Web of Science ®Google Scholar
• Oh E, Choi IK, Hong J, et al. Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model. Oncotarget. 2017 Jan 17;8(3):4730–4746.
   PubMedGoogle Scholar
• Nishio N, Diaconu I, Liu H, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014 Sep 15;74(18):5195–5205.
   PubMed Web of Science ®Google Scholar
• Cervera-Carrascon V, Siurala M, Santos JM, et al. TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology. 2018;7(5):e1412902.
   PubMed Web of Science ®Google Scholar
• Havunen R, Siurala M, Sorsa S, et al. Oncolytic adenoviruses armed with tumor necrosis factor alpha and Interleukin-2 enable successful adoptive cell therapy. Mol Ther Oncolytics. 2017 Mar 17;4:77–86.
   PubMed Web of Science ®Google Scholar
• Quixabeira DCA, Cervera-Carrascon V, Santos JM, et al. Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1. Oncoimmunology. 2022;11(1):2028960.
   PubMed Web of Science ®Google Scholar
• Kim W, Seong J, Oh HJ, et al. A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma. J Radiat Res. 2011;52(5):646–654.
   PubMed Web of Science ®Google Scholar
• Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA. 1996;93(24):13565–13570.
   PubMed Web of Science ®Google Scholar
• Morral N, Parks RJ, Zhou H, et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of α 1 -antitrypsin with Negligible toxicity. Hum Gene Ther. 1998;9(18):2709–2716.
   PubMed Web of Science ®Google Scholar
• Brunetti-Pierri N, Ng T, Iannitti D, et al. Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors. Hum Gene Ther. 2013 Aug;24(8):761–765.
   PubMed Web of Science ®Google Scholar
• Weaver EA, Nehete PN, Buchl SS, et al. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PloS one. 2009;4(3):e5059.
   PubMed Web of Science ®Google Scholar
• Weaver EA, Nehete PN, Nehete BP, et al. Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. PLoS One. 2013;8(7):e67574.
   PubMed Web of Science ®Google Scholar
• Harui A, Roth MD, Kiertscher SM, et al. Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL. Gene Ther. 2004 Nov;11(22):1617–1626.
   PubMed Web of Science ®Google Scholar
• Fu YH, He JS, Zheng XX, et al. Intranasal vaccination with a helper-dependent adenoviral vector enhances transgene-specific immune responses in BALB/c mice. Biochem Biophys Res Commun. 2010 Jan 1;391(1):857–861.
   PubMed Web of Science ®Google Scholar
• Rosewell Shaw A, Porter C, Biegert G, et al. HydrAd: a helper-dependent adenovirus targeting multiple immune pathways for cancer immunotherapy. Cancers (Basel). 2022 Jun 2;14(11):2769.
   PubMed Web of Science ®Google Scholar
• Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007 Jun;9(6):654–659.
   PubMed Web of Science ®Google Scholar
• Pandey MS, Wang C, Umlauf S, et al. Simultaneous inhibition of PD-1 and stimulation of CD40 signaling pathways by anti-PD-L1/CD40L bispecific fusion protein synergistically activate target and effector Cells. Int J Mol Sci. 2021 Oct 21;22(21):11302.
   PubMed Web of Science ®Google Scholar
• de Silva S, Fromm G, Shuptrine CW, et al. CD40 enhances type I interferon responses downstream of CD47 blockade, bridging innate and adaptive immunity. Cancer Immunol Res. 2020 Feb;8(2):230–245.
   PubMed Web of Science ®Google Scholar
• Fromm G, de Silva S, Johannes K, et al. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy. J Immunother Cancer. 2018 Dec 18;6(1):149.
   PubMedGoogle Scholar
• Guedan S, Alemany R. CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge. Front Immunol. 2018;9:2460.
   PubMed Web of Science ®Google Scholar
• Kuryk L, Moller AW, Jaderberg M. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. Oncoimmunology. 2019;8(2):e1532763.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xu W, Peng D, et al. An oncolytic adenovirus targeting transforming growth factor beta inhibits protumorigenic signals and produces immune activation: a novel approach to enhance anti-PD-1 and anti-CTLA-4 therapy. Hum Gene Ther. 2019 Sep;30(9):1117–1132.
   PubMed Web of Science ®Google Scholar
• Hu HJ, Liang X, Li HL, et al. Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model. Cancer Immunol Immunother. 2021 Dec;70(12):3541–3555.
   PubMed Web of Science ®Google Scholar
• Wenthe J, Naseri S, Hellstrom AC, et al. Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition. Mol Ther Oncolytics. 2022 Mar 17;24:429–442.
   PubMed Web of Science ®Google Scholar
• Zhang H, Xie W, Zhang Y, et al. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. Cancer Gene Ther. 2022 May;29(5):456–465.
   PubMed Web of Science ®Google Scholar
• Farrera-Sal M, Moya-Borrego L, Bazan-Peregrino M, et al. Evolving status of clinical immunotherapy with oncolytic adenovirus. Clin Cancer Res. 2021 Jun 1;27(11):2979–2988.
   PubMed Web of Science ®Google Scholar
• Mantwill K, Klein FG, Wang D, et al. Concepts in oncolytic adenovirus therapy. Int J Mol Sci. 2021 Sep 29;22(19):10522.
   PubMed Web of Science ®Google Scholar
• Young AM, Archibald KM, Tookman LA, et al. Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. Mol Ther. 2012 Sep;20(9):1676–1688.
   PubMed Web of Science ®Google Scholar
• Siurala M, Vaha-Koskela M, Havunen R, et al. Syngeneic Syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting. Oncoimmunology. 2016 May;5(5):e1136046.
   PubMed Web of Science ®Google Scholar
• McKenna MK, Rosewell-Shaw A, Suzuki M. Modeling the efficacy of oncolytic adenoviruses in vitro and in vivo: current and future perspectives. Cancers (Basel). 2020 Mar 7; 12(3):619.
   PubMed Web of Science ®Google Scholar
• Saruuldalai E, Park J, Kang D, et al. A host non-coding RNA, nc886, plays a pro-viral role by promoting virus trafficking to the nucleus. Mol Ther Oncolytics. 2022 Mar 17;24:683–694. .
   PubMed Web of Science ®Google Scholar
• Lei J, Jacobus EJ, Taverner WK, et al. Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells. J Immunother Cancer. 2018 Jun 13;6(1):55.
   PubMedGoogle Scholar
• Chartier C, Degryse E, Gantzer M, et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 1996 Jul;70(7):4805–4810.
   PubMed Web of Science ®Google Scholar
• Hamdan F, Martins B, Feodoroff M, et al. GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses. Mol Ther Methods Clin Dev. 2021 Mar 12;20:625–634.
   PubMed Web of Science ®Google Scholar
• Ni N, Deng F, He F, et al. A one-step construction of adenovirus (OSCA) system using the Gibson DNA assembly technology. Mol Ther Oncolytics. 2021 Dec 17;23:602–611. 10.1016/j.omto.2021.11.011.
   PubMed Web of Science ®Google Scholar
• Hatanaka K, Ohnami S, Yoshida K, et al. A simple and efficient method for constructing an adenoviral cDNA expression library. Mol Ther. 2003 Jul;8(1):158–166.
   PubMed Web of Science ®Google Scholar
• Rojas LA, Condezo GN, Moreno R, et al. Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery. J Control Release. 2016 Sep 10;237:78–88. 10.1016/j.jconrel.2016.07.004.
   PubMed Web of Science ®Google Scholar
• Hofherr SE, Shashkova EV, Weaver EA, et al. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther. 2008 Jul;16(7):1276–1282.
   PubMed Web of Science ®Google Scholar
• Schmid M, Ernst P, Honegger A, et al. Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control. Nat Commun. 2018 Jan 31;9(1):450.
   PubMedGoogle Scholar
• Yoon AR, Hong J, Kim SW, et al. Redirecting adenovirus tropism by genetic, chemical, and mechanical modification of the adenovirus surface for cancer gene therapy. Expert Opin Drug Deliv. 2016 Jun;13(6):843–858.
   PubMed Web of Science ®Google Scholar
• Barry MA, Rubin JD, Lu S-C. Retargeting adenoviruses for therapeutic applications and vaccines. FEBS Lett. 2020 Jun;594(12):1918–1946.
   PubMed Web of Science ®Google Scholar
• Saha B, Parks RJ, Nevels M. Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cells. PLoS One. 2017;12(7):e0181012.
   PubMed Web of Science ®Google Scholar
• Dhar D, Spencer JF, Toth K, et al. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol Ther. 2009 Oct;17(10):1724–1732. DOI:10.1038/mt.2009.156.
   PubMed Web of Science ®Google Scholar